Table 1 Patient characteristics.

From: Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis

 

PDC

Total

 ≥ 90%

80–< 90%

 < 80%

N

820

95

37

952

Age

 Mean ± SD

43.5 ± 12.0

43.5 ± 12.1

45.7 ± 13.2

43.6 ± 12.1

 18–29

104 (12.7%)

11 (11.6%)

3 (8.1%)

118 (12.4%)

 30–39

213 (26.0%)

23 (24.2%)

10 (27.0%)

246 (25.8%)

 40–49

270 (32.9%)

37 (38.9%)

11 (29.7%)

318 (33.4%)

 50–59

154 (18.8%)

16 (16.8%)

7 (18.9%)

177 (18.6%)

 60–69

61 (7.4%)

4 (4.2%)

3 (8.1%)

68 (7.1%)

 70-

18 (2.2%)

4 (4.2%)

3 (8.1%)

25 (2.6%)

Comorbidity

 Renal disease (Yes)

25 (3.0%)

0 (0.0%)

0 (0.0%)

25 (2.6%)

 Mental disease (Yes)

101 (12.3%)

19 (20.0%)

10 (27.0%)

130 (13.7%)

 Metabolic disease (Yes)

256 (31.2%)

33 (34.7%)

12 (32.4%)

301 (31.6%)

 Cardiovascular disease (Yes)

138 (16.8%)

17 (17.9%)

6 (16.2%)

161 (16.9%)

 Hepatitis B virus (Yes)

97 (11.8%)

11 (11.6%)

7 (18.9%)

115 (12.1%)

Pill number burden

 Mean ± SD

1.9 ± 2.9

2.1 ± 2.5

2.4 ± 3.7

1.9 ± 2.9

 0

382 (46.6%)

40 (42.1%)

17 (45.9%)

439 (46.1%)

 1–2

225 (27.4%)

25 (26.3%)

9 (24.3%)

259 (27.2%)

 3-

213 (26.0%)

30 (31.6%)

11 (29.7%)

254 (26.7%)

ART experience

 Naïve

253 (30.9%)

17 (17.9%)

11 (29.7%)

281 (29.5%)

 Experienced

567 (69.1%)

78 (82.1%)

26 (70.3%)

671 (70.5%)

AIDS-defining condition (Yes)

318 (38.8%)

35 (36.8%)

12 (32.4%)

365 (38.3%)

  1. The data are presented as the number (%) of patients unless otherwise noted.
  2. AIDS acquired immunodeficiency syndrome, ART antiretroviral therapy, PDC proportion of days covered, SD standard deviation.
Back to article page